trending Market Intelligence /marketintelligence/en/news-insights/trending/GJdJ6t4-iQvWfLp4y90yDQ2 content esgSubNav
In This List

Novartis exercises license for eye drug

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Novartis exercises license for eye drug

A Novartis AG unit exercised its option to in-license ECF843 from Lubris LLC for ophthalmic indications in all regions outside Europe.

ECF843, which underwent a small phase 2 study, is being developed as a potential treatment for dry eye, an eye syndrome caused by chronic lack of moisture on the eye surface.

Novartis International AG already has several drugs to treat dry eye conditions including Systane, Tears Naturale, and Genteal. It did not disclose the financial terms of the transaction.